This company may still be operating, however this listing is no longer active. Find out why through their latest events.

TCR2 Therapeutics Zukünftiges Wachstum

We currently don't have sufficient analyst coverage to forecast growth and revenue for TCR2 Therapeutics.

5.0%

Wachstumsrate der Gewinne

22.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	30.4%
Wachstumsrate der Einnahmen	87.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	n/a

Keine Aktualisierungen

Gewinn- und Umsatzwachstumsprognosen

MUN:2K7 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2024	10	-169	-142	-131	5
12/31/2023	N/A	-149	-128	-123	7
12/31/2022	N/A	-127	-118	-114	8
6/30/2022	N/A	-115	-111	-93	N/A
3/31/2022	N/A	-107	-101	-89	N/A
12/31/2021	N/A	-100	-93	-82	N/A
9/30/2021	N/A	-91	-81	-72	N/A
6/30/2021	N/A	-81	-72	-63	N/A
3/31/2021	N/A	-73	-72	-64	N/A
12/31/2020	N/A	-67	-64	-57	N/A
9/30/2020	N/A	-61	-57	-54	N/A
6/30/2020	N/A	-58	-57	-53	N/A
3/31/2020	N/A	-53	-51	-47	N/A
12/31/2019	N/A	-97	-45	-41	N/A
9/30/2019	N/A	-96	-41	-37	N/A
6/30/2019	N/A	-100	-33	-32	N/A
3/31/2019	N/A	-107	-27	-27	N/A
12/31/2018	N/A	-62	-20	-19	N/A
9/30/2018	N/A	-55	-18	-17	N/A
12/31/2017	N/A	-15	-12	-12	N/A

Einkommen vs. Sparrate: 2K7 is forecast to remain unprofitable over the next 3 years.

Ertrag vs. Markt: 2K7 is forecast to remain unprofitable over the next 3 years.

Hohe Wachstumserträge: 2K7 is forecast to remain unprofitable over the next 3 years.

Einnahmen vs. Markt: 2K7 is forecast to have no revenue next year.

Hohe Wachstumseinnahmen: 2K7 is forecast to have no revenue next year.

Künftige Eigenkapitalrendite: Insufficient data to determine if 2K7's Return on Equity is forecast to be high in 3 years time